Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK008 haploidentical HCT with or without HSV-TK donor lymphocyte add-back
2009-012973-37Phase 3Terminated
- Sponsor
- MolMed
- Start
- Dec 2009
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nalotimagene carzadenotucel in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by MolMed. Primary endpoint: 1-year cumulative incidence of non-relapse mortality. Started Dec 2009; status: terminated.
02
Drugs
nalotimagene carzadenotucel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-012973-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012973-37.